美国 · 平台与数据 · Morningstar

Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma

来源：Morningstar · 美国 10 小时前

Supports serial testing in the surveillance setting for patients with early-stage HCC Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today…

在 Morningstar 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.morningstar.com)

Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma

推荐阅读

SpaceX Sent Verizon and T-Mobile Stocks Tumbling—Did Wall Street Overreact?

Tech borrowers are picking up the tab: debt premium hits a 23-year high

Texas governor race tightens in prediction markets, but Abbott remains favored

ICF vs. HAUZ: ICF Beats on Returns, but HAUZ Dominates on Fees and Yield

It’s finally Election Day — and prediction markets may show ‘too much confidence in a good night for Democrats’

Treasury yields edge up as Election Day meets JOLTS, refunding

Medicare Expands Coverage for Signatera™ MRD Test in Hepatocellular Carcinoma

分享

推荐阅读

SpaceX Sent Verizon and T-Mobile Stocks Tumbling—Did Wall Street Overreact?

Tech borrowers are picking up the tab: debt premium hits a 23-year high

Texas governor race tightens in prediction markets, but Abbott remains favored

ICF vs. HAUZ: ICF Beats on Returns, but HAUZ Dominates on Fees and Yield

It’s finally Election Day — and prediction markets may show ‘too much confidence in a good night for Democrats’

Treasury yields edge up as Election Day meets JOLTS, refunding